2,849 press releases indexed under healthcare.
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson
As Southern Utah temperatures climb, St. George foot and ankle clinic highlights how extreme heat can affect foot and ankle health and ways to lower risk. The post Foot & Ankle Center Warns Southern Utah Residents of Overlooked Summer Heat Risks first appeared on
(PR-inside.com) MALMÖ, SE / ACCESS Newswire / July 15, 2026 / Ascelia Pharma (STO:ACE), a biotech company focused on improving the lives of people with rare cancer conditions, today announces that CFO Anton Hansson will be leaving the Company. In connection with this change and cost reduction initiatives, Ascelia Pharma is reducing its cost base while focusing on the path forward for Orviglance®. The changes support alignment of resources with Ascelia Pharma's current priorities, including regulatory interactions with the U.S. Food and Drug Administration ("FDA") and bringing Orviglance to patients. "Our focus is on the upcoming Type A meeting with the FDA where ..
(PR-inside.com) WOODSTOCK, GA / ACCESS Newswire / July 15, 2026 / SlicedHealth has launched GROW, an operational platform designed to give small and mid-sized hospitals the same clarity and control over contracts, credentialing, and compliance that has traditionally only been available to much larger health systems. GROW connects agreements to the day to day activity they are supposed to govern, so a hospital can see not just what a contract says, but whether it is actually being honored in practice. For years, the advice to rural and community hospitals was simple. Protect your margin, control your costs, and keep the doors open. ..
(PR-inside.com) Completed Independent Study Strongly Supports Favorable Payor Receptivity to Pivot's Differentiated Design and Simplified User Experience, and provides further validation of significant progress towards goal of achieving broad market access for Pivot SAN DIEGO, CA / ACCESS Newswire / July 15, 2026 / Modular Medical, Inc. ("Modular Medical" or "the Company") (NASDAQ:MODD), a commercial-stage medical device company that is commercializing the next generation of insulin delivery technology, today released findings from an independent market research study demonstrating positive receptivity to its FDA-cleared Pivot™ tubeless patch pump due to its differentiated design, streamlined user experience, and potential for reimbursement through the pharmacy ..
CARACAS, VENEZUELA - July 15, 2026 ( NEWMEDIAWIRE ) - LataMed AI Corp. (OTC: LMEDD) (the “Company”) today announced that its previously announced 5-for-1 forward stock split has become effective at the opening of trading following publication of the corporate action on the FINRA Daily List dated July 14, 2026. In connection with the forward stock split, the Company's common stock will begin trading today under the temporary trading symbol LMEDD . The temporary "D" designation is a standard FINRA identifier used in connection with certain corporate actions and is expected to remain in place for approximately twenty (20) business days, after which the trading symbol is expected to revert to LMED . The forward stock split has also been implemented in conjunction with the Company's mandatory s
Completed Independent Study Strongly Supports Favorable Payor Receptivity to Pivot's Differentiated Design and Simplified User Experience, and provides further validation of significant progress towards goal of achieving broad market access for Pivot
Company expands support for CMS' ACCESS Model and the Medicare GLP-1 Bridge, helping healthcare organizations operationalize technology-enabled, longitudinal care at scale AUSTIN, Texas, July 15, 2026 /PRNewswire-PRWeb/ -- Wheel, the leading clinical infrastructure company powering...
BEIJING, July 15, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that registrational phase III clinical study results of novel TYK2 (Tyrosine Kinase 2) inhibitor soficitinib (ICP-332) met the primary endpoint in patients with moderate-to-severe atopic dermatitis (AD).
Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company Advances Toward IND
First patients dosed in Switzerland SHELTON, Conn., July 15, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that...
TORONTO, July 15, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that its MRI-guided, AI-powered, Robotically-Driven and Incisionless TULSA Procedure™ will be highlighted in several presentations by leading physicians at the upcoming Society of Robotic Surgery (“SRS”) Annual Meeting to be held in Fort Lauderdale, FL, July 23-26, 2026.*